PATENT CLAIM ANALYSIS

Application Number: 15889584
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "093710"]

Abstract:
The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.

Claim (Index 3):
The method of  claim 1 , wherein the introducing of the immature dendritic cells and/or CTLs, is coincident with the introducing of the anti-TNF antibody.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 2.15
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14549706', '13928844', '13303679', '12100878', '13504447']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7979323716431791
- 35 USC 102 Novelty (BERT): 0.6041594667805253
- Combined Prediction Score: 0.7785550811569137
- Mean Citation Score: 404.299358
- Max Citation Score: 567.3949
- Similarity Product: 455.54679831388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test